Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Javier OesterheldWilliam FergusonJacqueline M KravekaGenevieve BergendahlThomas ClinchElizabeth LorenziDonald A BerryRandal K WadaMichael S IsakoffDon E EslinValerie I BrownWilliam RobertsPeter ZageVirginia L HarrodDeanna S MitchellDerek HansonGiselle L Saulnier ShollerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The externally controlled analyses presented show a relapse risk reduction in patients with HRNB treated with postimmunotherapy DFMO.
Keyphrases